| Code | CSB-RA023986MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to GB-223, developed to specifically target TNFSF11, also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). TNFSF11 is a critical cytokine member of the tumor necrosis factor superfamily that plays an essential role in osteoclast differentiation, activation, and survival. By binding to its receptor RANK, TNFSF11 regulates bone remodeling and calcium metabolism, making it a key mediator in skeletal homeostasis. Dysregulation of TNFSF11 signaling is implicated in various pathological conditions including osteoporosis, rheumatoid arthritis, bone metastases, and metabolic bone diseases.
GB-223, the reference antibody also known as denosumab, is a well-characterized therapeutic monoclonal antibody that neutralizes TNFSF11 activity by preventing its interaction with RANK. This biosimilar provides researchers with a cost-effective tool for investigating RANKL-mediated signaling pathways, studying bone metabolism mechanisms, exploring osteoclast biology, and evaluating potential therapeutic interventions in bone-related disorders and cancer research models.
There are currently no reviews for this product.